Glenview Trust Co purchased a new stake in Humana Inc. (NYSE:HUM – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 43,688 shares of the insurance provider’s stock, valued at approximately $17,354,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Montag A & Associates Inc. raised its holdings in Humana by 1,880.0% in the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock valued at $25,000 after buying an additional 94 shares during the period. Johnson Financial Group Inc. purchased a new position in Humana during the second quarter worth about $26,000. Fideuram Asset Management Ireland dac acquired a new stake in shares of Humana during the fourth quarter valued at about $27,000. Trust Co. of Vermont acquired a new stake in shares of Humana during the second quarter valued at about $28,000. Finally, Reflection Asset Management purchased a new stake in shares of Humana in the 4th quarter valued at approximately $29,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.
Humana Stock Performance
Shares of HUM stock opened at $392.72 on Friday. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.62. Humana Inc. has a 52 week low of $163.11 and a 52 week high of $428.88. The stock has a market capitalization of $47.16 billion, a PE ratio of 37.15, a P/E/G ratio of 2.23 and a beta of 0.72. The firm has a 50 day moving average of $385.08 and a two-hundred day moving average of $287.78.
Analysts Set New Price Targets
A number of research analysts have commented on HUM shares. Truist Financial upped their price target on Humana from $320.00 to $415.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. The Goldman Sachs Group lifted their price objective on Humana from $158.00 to $195.00 and gave the company a “sell” rating in a research note on Thursday, April 30th. Deutsche Bank Aktiengesellschaft began coverage on Humana in a report on Thursday, July 30th. They issued a “hold” rating on the stock. Raymond James Financial lowered Humana from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 30th. Finally, Robert W. Baird set a $390.00 target price on Humana in a report on Thursday, July 30th. Fourteen research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $403.91.
Check Out Our Latest Research Report on Humana
About Humana
Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Further Reading
- Five stocks we like better than Humana
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
